{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:59:46Z","timestamp":1785139186982,"version":"3.55.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00705-026-06667-5","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:22:40Z","timestamp":1781112160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 3CL protease interaction with host factors \u2013 identifying novel drug targets"],"prefix":"10.1007","volume":"171","author":[{"given":"Debosmita","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-6238","authenticated-orcid":false,"given":"Binay","family":"Chaubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"6667_CR1","doi-asserted-by":"publisher","first-page":"e10396","DOI":"10.15252\/msb.202110396","volume":"17","author":"X Liu","year":"2021","unstructured":"Liu X, Huuskonen S, Laitinen T et al (2021) SARS-CoV\u20102\u2013host proteome interactions for antiviral drug discovery. Mol Syst Biol 17:e10396. https:\/\/doi.org\/10.15252\/msb.202110396","journal-title":"Mol Syst Biol"},{"key":"6667_CR2","doi-asserted-by":"publisher","first-page":"165878","DOI":"10.1016\/j.bbadis.2020.165878","volume":"1866","author":"AAT Naqvi","year":"2020","unstructured":"Naqvi AAT, Fatima K, Mohammad T et al (2020) Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta - Mol Basis Dis 1866:165878. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165878","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"6667_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459\u2013468. https:\/\/doi.org\/10.1038\/s41586-020-2286-9","journal-title":"Nature"},{"key":"6667_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/J.CELL.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D, Lee JY, Yang JS et al (2020) The Architecture of SARS-CoV-2 Transcriptome. Cell 181:914\u2013921. https:\/\/doi.org\/10.1016\/J.CELL.2020.04.011. .e10","journal-title":"Cell"},{"key":"6667_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cells9051267","volume":"9","author":"M Romano","year":"2020","unstructured":"Romano M, Ruggiero A, Squeglia F et al (2020) A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells 9:1267. https:\/\/doi.org\/10.3390\/cells9051267","journal-title":"Cells"},{"key":"6667_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41579-022-00839-1","volume":"213 21","author":"JM Minkoff","year":"2023","unstructured":"Minkoff JM, tenOever B (2023) Innate immune evasion strategies of SARS-CoV-2. Nat Rev Microbiol 2023 213 21:178\u2013194. https:\/\/doi.org\/10.1038\/s41579-022-00839-1","journal-title":"Nat Rev Microbiol 2023"},{"key":"6667_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/22221751.2020.1870414","volume":"10","author":"M Moustaqil","year":"2021","unstructured":"Moustaqil M, Ollivier E, Chiu HP et al (2021) SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and Table 1): implications for disease presentation across species. Emerg Microbes Infect 10:178\u2013195. https:\/\/doi.org\/10.1080\/22221751.2020.1870414","journal-title":"Emerg Microbes Infect"},{"key":"6667_CR8","doi-asserted-by":"publisher","first-page":"FSO853","DOI":"10.2144\/fsoa-2023-0020","volume":"9","author":"Y Kuang","year":"2023","unstructured":"Kuang Y, Ma X, Shen W et al (2023) Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease. Futur Sci OA 9:FSO853. https:\/\/doi.org\/10.2144\/fsoa-2023-0020","journal-title":"Futur Sci OA"},{"key":"6667_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1039\/d2md00344a","volume":"14","author":"R Chen","year":"2023","unstructured":"Chen R, Gao Y, Liu H et al (2023) Advances in research on 3\u00a0C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020. Med Chem (Los Angeles) 14:9\u201321. https:\/\/doi.org\/10.1039\/d2md00344a","journal-title":"Med Chem (Los Angeles)"},{"key":"6667_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/ijms23010259","volume":"23","author":"G Macip","year":"2022","unstructured":"Macip G, Garcia-segura P, Mestres-truyol J et al (2022) A review of the current landscape of SARS-CoV-2 main protease inhibitors: Have we hit the bullseye yet? Int J Mol Sci 23:259. https:\/\/doi.org\/10.3390\/ijms23010259","journal-title":"Int J Mol Sci"},{"key":"6667_CR11","doi-asserted-by":"publisher","unstructured":"Mody V, Ho J, Wills S et al (2021) Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 41:4\u201393. https:\/\/doi.org\/10.1038\/s42003-020-01577-x","DOI":"10.1038\/s42003-020-01577-x"},{"key":"6667_CR12","doi-asserted-by":"publisher","first-page":"114367","DOI":"10.1016\/j.biopha.2023.114367","volume":"162","author":"SMR Hashemian","year":"2023","unstructured":"Hashemian SMR, Sheida A, Taghizadieh M et al (2023) Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy? Biomed Pharmacother 162:114367. https:\/\/doi.org\/10.1016\/j.biopha.2023.114367","journal-title":"Biomed Pharmacother"},{"key":"6667_CR13","doi-asserted-by":"publisher","unstructured":"Gao C, Liu Z, Zou Z et al (2025) Effects of nirmatrelvir\/ritonavir (Paxlovid) on the nervous system: analysis on adverse events released by FDA. Expert Opin Drug Saf 1\u20138. https:\/\/doi.org\/10.1080\/14740338.2025.2471509","DOI":"10.1080\/14740338.2025.2471509"},{"key":"6667_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s43856-024-00668-8","volume":"41 4","author":"AK Cohen","year":"2025","unstructured":"Cohen AK, Jaudon TW, Schurman EM et al (2025) Impact of extended-course oral nirmatrelvir\/ritonavir in established Long COVID: a case series. Commun Med 2025 41 4:261\u2013. https:\/\/doi.org\/10.1038\/s43856-024-00668-8","journal-title":"Commun Med 2025"},{"key":"6667_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/molecules30040805","volume":"30","author":"J Chen","year":"2025","unstructured":"Chen J, Wang J, Yang W et al (2025) Identifying Inhibitor-SARS-CoV2-3CLpro Binding Mechanism Through Molecular Docking, GaMD Simulations, Correlation Network Analysis and MM-GBSA Calculations. Molecules 30:805. https:\/\/doi.org\/10.3390\/molecules30040805","journal-title":"Molecules"},{"key":"6667_CR16","doi-asserted-by":"publisher","first-page":"e202405868","DOI":"10.1002\/slct.202405868","volume":"10","author":"C Jia","year":"2025","unstructured":"Jia C, Sun Y, Chen J, Liu X (2025) Dissecting the Molecular Mechanism Concerning Conformational Changes of SARS-CoV-2 Main Protease Mediated by Binding of Natural Phytochemicals via Molecular Dynamics Simulations. ChemistrySelect 10:e202405868. https:\/\/doi.org\/10.1002\/slct.202405868","journal-title":"ChemistrySelect"},{"key":"6667_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-023-05469-8","volume":"61 6","author":"A Aniana","year":"2023","unstructured":"Aniana A, Nashed NT, Ghirlando R et al (2023) Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors. Commun Biol 2023 61 6:1\u201314. https:\/\/doi.org\/10.1038\/s42003-023-05469-8","journal-title":"Commun Biol 2023"},{"key":"6667_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Sci (80) 368:409\u2013412","journal-title":"Sci (80)"},{"key":"6667_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293. https:\/\/doi.org\/10.1038\/s41586-020-2223-y","journal-title":"Nature"},{"key":"6667_CR20","doi-asserted-by":"publisher","first-page":"24765","DOI":"10.1074\/JBC.M311744200\/ASSET\/7451176E-00D2-444E-AA97-6420B5FC931B\/MAIN.ASSETS\/GR9.JPG","volume":"279","author":"J Shi","year":"2004","unstructured":"Shi J, Wei Z, Song J (2004) Dissection study on the severe acute respiratory syndrome 3\u00a0C-like protease reveals the critical role of the extra domain in dimerization of the enzyme. Defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem 279:24765\u201324773. https:\/\/doi.org\/10.1074\/JBC.M311744200\/ASSET\/7451176E-00D2-444E-AA97-6420B5FC931B\/MAIN.ASSETS\/GR9.JPG","journal-title":"J Biol Chem"},{"key":"6667_CR21","doi-asserted-by":"publisher","first-page":"131392","DOI":"10.1016\/J.IJBIOMAC.2024.131392","volume":"267","author":"K Lis","year":"2024","unstructured":"Lis K, Plewka J, Menezes F et al (2024) SARS-CoV-2 Mpro oligomerization as a potential target for therapy. Int J Biol Macromol 267:131392. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2024.131392","journal-title":"Int J Biol Macromol"},{"key":"6667_CR22","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","volume":"3","author":"H Yang","year":"2005","unstructured":"Yang H, Xie W, Xue X et al (2005) Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases. PLoS Biol 3:e324. https:\/\/doi.org\/10.1371\/journal.pbio.0030324","journal-title":"PLoS Biol"},{"key":"6667_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.JPHA.2020.03.009","volume":"10","author":"M Tahir ul Qamar","year":"2020","unstructured":"Tahir ul Qamar M, Alqahtani SM, Alamri MA, Chen LL (2020) Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 10:313\u2013319. https:\/\/doi.org\/10.1016\/J.JPHA.2020.03.009","journal-title":"J Pharm Anal"},{"key":"6667_CR24","doi-asserted-by":"publisher","first-page":"e02878","DOI":"10.1128\/mbio.02878-23","volume":"15","author":"P Li","year":"2024","unstructured":"Li P, Kim Y, Dampalla CS et al (2024) Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment. MBio 15:e02878\u2013e02823. https:\/\/doi.org\/10.1128\/mbio.02878-23","journal-title":"MBio"},{"key":"6667_CR25","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","volume":"21","author":"K Anand","year":"2002","unstructured":"Anand K, Palm GJ, Mesters JR et al (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra \u03b1-helical domain. EMBO J 21:3213\u20133224. https:\/\/doi.org\/10.1093\/emboj\/cdf327","journal-title":"EMBO J"},{"key":"6667_CR26","doi-asserted-by":"publisher","first-page":"108079","DOI":"10.1016\/J.JBC.2024.108079","volume":"301","author":"P Novotn\u00fd","year":"2025","unstructured":"Novotn\u00fd P, Humpol\u00ed\u010dkov\u00e1 J, Nov\u00e1kov\u00e1 V et al (2025) The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery. J Biol Chem 301:108079. https:\/\/doi.org\/10.1016\/J.JBC.2024.108079","journal-title":"J Biol Chem"},{"key":"6667_CR27","doi-asserted-by":"publisher","unstructured":"Paciaroni A, Libera V, Ripanti F et al (2023) Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir. Int J Mol Sci 24:6062. https:\/\/doi.org\/10.3390\/IJMS24076062","DOI":"10.3390\/IJMS24076062"},{"key":"6667_CR28","doi-asserted-by":"publisher","first-page":"e70275","DOI":"10.1002\/PRO.70275","volume":"34","author":"G Wang","year":"2025","unstructured":"Wang G, Venegas F, Rueda A et al (2025) Inhibitor-induced dimerization mediates lufotrelvir resistance in mutants of SARS-CoV-2 3\u00a0C-like protease. Protein Sci 34:e70275. https:\/\/doi.org\/10.1002\/PRO.70275","journal-title":"Protein Sci"},{"key":"6667_CR29","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/j.bpj.2025.06.040","volume":"124","author":"VNT La","year":"2025","unstructured":"La VNT, Kang L, Minh DDL (2025) Enzyme kinetics model for the coronavirus main protease including dimerization and ligand binding. Biophys J 124:2627\u20132638. https:\/\/doi.org\/10.1016\/j.bpj.2025.06.040","journal-title":"Biophys J"},{"key":"6667_CR30","doi-asserted-by":"publisher","first-page":"28140","DOI":"10.1074\/jbc.M109.095851","volume":"285","author":"C Li","year":"2010","unstructured":"Li C, Qi Y, Teng X et al (2010) Maturation Mechanism of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3\u00a0C-like Proteinase. J Biol Chem 285:28140. https:\/\/doi.org\/10.1074\/jbc.M109.095851","journal-title":"J Biol Chem"},{"key":"6667_CR31","doi-asserted-by":"publisher","first-page":"13894","DOI":"10.1074\/jbc.M510745200","volume":"281","author":"H Chen","year":"2006","unstructured":"Chen H, Wei P, Huang C et al (2006) Only one protomer is active in the dimer of SARS 3\u00a0C-like proteinase. J Biol Chem 281:13894\u201313898. https:\/\/doi.org\/10.1074\/jbc.M510745200","journal-title":"J Biol Chem"},{"key":"6667_CR32","doi-asserted-by":"publisher","first-page":"102023","DOI":"10.1016\/j.jbc.2022.102023","volume":"298","author":"JC Ferreira","year":"2022","unstructured":"Ferreira JC, Fadl S, Rabeh WM (2022) Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2. J Biol Chem 298:102023. https:\/\/doi.org\/10.1016\/j.jbc.2022.102023","journal-title":"J Biol Chem"},{"key":"6667_CR33","doi-asserted-by":"publisher","first-page":"9283","DOI":"10.1038\/s41598-021-88630-9","volume":"111 11","author":"L Silvestrini","year":"2021","unstructured":"Silvestrini L, Belhaj N, Comez L et al (2021) The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. Sci Rep 2021 111 11:9283\u2013. https:\/\/doi.org\/10.1038\/s41598-021-88630-9","journal-title":"Sci Rep 2021"},{"key":"6667_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/SCIENCE.ABB4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai W, Zhang B, Jiang XM et al (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Sci (80) 368:1331\u20131335. https:\/\/doi.org\/10.1126\/SCIENCE.ABB4489","journal-title":"Sci (80)"},{"key":"6667_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"I Schechter","year":"1967","unstructured":"Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157\u2013162. https:\/\/doi.org\/10.1016\/S0006-291X(67)80055-X","journal-title":"Biochem Biophys Res Commun"},{"key":"6667_CR36","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/ACS.JMEDCHEM.5B01461\/SUPPL_FILE\/JM5B01461_SI_001.PDF","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar T, Manickam M, Namasivayam V et al (2016) An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. J Med Chem 59:6595\u20136628. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.5B01461\/SUPPL_FILE\/JM5B01461_SI_001.PDF","journal-title":"J Med Chem"},{"key":"6667_CR37","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/MED.21783","volume":"41","author":"M Xiong","year":"2021","unstructured":"Xiong M, Su H, Zhao W et al (2021) What coronavirus 3\u00a0C-like protease tells us: From structure, substrate selectivity, to inhibitor design. Med Res Rev 41:1965\u20131998. https:\/\/doi.org\/10.1002\/MED.21783","journal-title":"Med Res Rev"},{"key":"6667_CR38","doi-asserted-by":"publisher","first-page":"805472","DOI":"10.3389\/FMICB.2021.805472\/BIBTEX","volume":"12","author":"W Xue","year":"2022","unstructured":"Xue W, Ding C, Qian K, Liao Y (2022) The Interplay Between Coronavirus and Type I IFN Response. Front Microbiol 12:805472. https:\/\/doi.org\/10.3389\/FMICB.2021.805472\/BIBTEX","journal-title":"Front Microbiol"},{"key":"6667_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17665-9","volume":"11","author":"X Lei","year":"2020","unstructured":"Lei X, Dong X, Ma R et al (2020) Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 11:3810:1\u201312. https:\/\/doi.org\/10.1038\/s41467-020-17665-9","journal-title":"Nat Commun"},{"key":"6667_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00332-2","volume":"5","author":"Y Wu","year":"2020","unstructured":"Wu Y, Ma L, Zhuang Z et al (2020) Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal Transduct Target Ther 5:221:1\u20133. https:\/\/doi.org\/10.1038\/s41392-020-00332-2","journal-title":"Signal Transduct Target Ther"},{"key":"6667_CR41","doi-asserted-by":"publisher","first-page":"102990","DOI":"10.1016\/J.JBC.2023.102990","volume":"299","author":"L Song","year":"2023","unstructured":"Song L, Wang D, Abbas G et al (2023) The main protease of SARS-CoV-2 cleaves histone deacetylases and DCP1A, attenuating the immune defense of the interferon-stimulated genes. J Biol Chem 299:102990. https:\/\/doi.org\/10.1016\/J.JBC.2023.102990","journal-title":"J Biol Chem"},{"key":"6667_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pmic.202000246","volume":"21","author":"T Koudelka","year":"2021","unstructured":"Koudelka T, Boger J, Henkel A et al (2021) N-Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease. Proteomics 21:2\u20136. https:\/\/doi.org\/10.1002\/pmic.202000246","journal-title":"Proteomics"},{"issue":"6","key":"6667_CR43","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.7150\/ijbs.59943","volume":"17","author":"S-Y Fung","year":"2021","unstructured":"Fung S-Y, Siu K-L, Lin H et al (2021) SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3. Int J Biol Sci 17(6):1547\u20131554. https:\/\/doi.org\/10.7150\/ijbs.59943","journal-title":"Int J Biol Sci"},{"key":"6667_CR44","doi-asserted-by":"publisher","first-page":"02335","DOI":"10.1128\/mBio.02335-21","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Qin C, Rao Y et al (2021) SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS to Evade the Innate Immune Response. MBio 12:02335\u201302321. https:\/\/doi.org\/10.1128\/mBio.02335-21","journal-title":"MBio"},{"key":"6667_CR45","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1002\/MEF2.29","volume":"1","author":"M Wang","year":"2022","unstructured":"Wang M, Zhao Y, Liu J, Li T (2022) SARS-CoV-2 modulation of RIG-I-MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches. MedComm \u2013 Futur Med 1:e29. https:\/\/doi.org\/10.1002\/MEF2.29","journal-title":"MedComm \u2013 Futur Med"},{"key":"6667_CR46","doi-asserted-by":"publisher","first-page":"750969","DOI":"10.3389\/fimmu.2021.750969","volume":"12","author":"W Li","year":"2021","unstructured":"Li W, Qiao J, You Q et al (2021) SARS-CoV-2 Nsp5 Activates NF-\u03baB Pathway by Upregulating SUMOylation of MAVS. Front Immunol 12:750969. https:\/\/doi.org\/10.3389\/fimmu.2021.750969","journal-title":"Front Immunol"},{"issue":"6738","key":"6667_CR47","doi-asserted-by":"publisher","first-page":"eadl0429","DOI":"10.1126\/science.adl0429","volume":"386","author":"NS Gokhale","year":"2024","unstructured":"Gokhale NS, Sam RK, Somfleth K et al (2024) Cellular RNA interacts with MAVS to promote antiviral signaling. Science 386(6738):eadl0429. https:\/\/doi.org\/10.1126\/science.adl0429","journal-title":"Science"},{"key":"6667_CR48","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrm3011","volume":"11","author":"JR Gareau","year":"2010","unstructured":"Gareau JR, Lima CD (2010) The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11:861. https:\/\/doi.org\/10.1038\/nrm3011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6667_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/S41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L et al (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20:363. https:\/\/doi.org\/10.1038\/S41577-020-0311-8","journal-title":"Nat Rev Immunol"},{"key":"6667_CR50","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/j.molcel.2022.04.033","volume":"82","author":"R Plan\u00e8s","year":"2022","unstructured":"Plan\u00e8s R, Pinilla M, Santoni K et al (2022) Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells. Mol Cell 82:2385\u20132400e9. https:\/\/doi.org\/10.1016\/j.molcel.2022.04.033","journal-title":"Mol Cell"},{"key":"6667_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-022-00878-3","volume":"71 7","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Deng J, Han L et al (2022) SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules. Signal Transduct Target Ther 2022 71 7:22. https:\/\/doi.org\/10.1038\/s41392-022-00878-3","journal-title":"Signal Transduct Target Ther 2022"},{"key":"6667_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25796-w","volume":"12","author":"B Meyer","year":"2021","unstructured":"Meyer B, Chiaravalli J, Gellenoncourt S et al (2021) Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential. Nat Commun 12:1\u201316. https:\/\/doi.org\/10.1038\/s41467-021-25796-w","journal-title":"Nat Commun"},{"key":"6667_CR53","doi-asserted-by":"publisher","first-page":"109892","DOI":"10.1016\/j.celrep.2021.109892","volume":"37","author":"I Pablos","year":"2021","unstructured":"Pablos I, Machado Y, de Jesus HCR et al (2021) Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. Cell Rep 37:109892. https:\/\/doi.org\/10.1016\/j.celrep.2021.109892","journal-title":"Cell Rep"},{"key":"6667_CR54","doi-asserted-by":"publisher","first-page":"109986","DOI":"10.1016\/J.VIROL.2024.109986","volume":"592","author":"NH Altina","year":"2024","unstructured":"Altina NH, Maranon DG, Anderson JR et al (2024) The leader RNA of SARS-CoV-2 sequesters polypyrimidine tract binding protein (PTBP1) and influences pre-mRNA splicing in infected cells. Virology 592:109986. https:\/\/doi.org\/10.1016\/J.VIROL.2024.109986","journal-title":"Virology"},{"key":"6667_CR55","doi-asserted-by":"publisher","first-page":"113926","DOI":"10.1016\/j.celrep.2024.113926","volume":"43","author":"Z Zhong","year":"2024","unstructured":"Zhong Z, Jiao Z, Yu F-X (2024) The Hippo signaling pathway in development and regeneration. CellReports 43:113926. https:\/\/doi.org\/10.1016\/j.celrep.2024.113926","journal-title":"CellReports"},{"key":"6667_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/GAD.274027.115","volume":"30","author":"Z Meng","year":"2016","unstructured":"Meng Z, Moroishi T, Guan KL (2016) Mechanisms of Hippo pathway regulation. Genes Dev 30:1\u201317. https:\/\/doi.org\/10.1101\/GAD.274027.115","journal-title":"Genes Dev"},{"key":"6667_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/J.TCB.2019.10.005","volume":"30","author":"V Rausch","year":"2020","unstructured":"Rausch V, Hansen CG (2020) The Hippo Pathway, YAP\/TAZ, and the Plasma Membrane. Trends Cell Biol 30:32\u201348. https:\/\/doi.org\/10.1016\/J.TCB.2019.10.005","journal-title":"Trends Cell Biol"},{"key":"6667_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.2021107776","volume":"40","author":"Z Chen","year":"2021","unstructured":"Chen Z, Wang C, Feng X et al (2021) Interactomes of SARS-CoV\u20102 and human coronaviruses reveal host factors potentially affecting pathogenesis. EMBO J 40:1\u201319. https:\/\/doi.org\/10.15252\/embj.2021107776","journal-title":"EMBO J"},{"key":"6667_CR59","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1021\/ACSINFECDIS.2C00458","volume":"9","author":"SY Luo","year":"2023","unstructured":"Luo SY, Moussa EW, Lopez-Orozco J et al (2023) Identification of Human Host Substrates of the SARS-CoV-2 Mpro and PLpro Using Subtiligase N-Terminomics. ACS Infect Dis 9:749\u2013761. https:\/\/doi.org\/10.1021\/ACSINFECDIS.2C00458","journal-title":"ACS Infect Dis"},{"key":"6667_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41392-023-01418-3","volume":"8","author":"W Liang","year":"2023","unstructured":"Liang W, Gu M, Zhu L et al (2023) The main protease of SARS-CoV-2 downregulates innate immunity via a translational repression. Signal Transduct Target Ther 8:1\u20134. https:\/\/doi.org\/10.1038\/S41392-023-01418-3","journal-title":"Signal Transduct Target Ther"},{"key":"6667_CR61","doi-asserted-by":"publisher","first-page":"e2107108118","DOI":"10.1073\/PNAS.2107108118","volume":"118","author":"S Zhang","year":"2021","unstructured":"Zhang S, Wang J, Cheng G (2021) Protease cleavage of RNF20 facilitates coronavirus replication via stabilization of SREBP1. Proc Natl Acad Sci U S A 118:e2107108118. https:\/\/doi.org\/10.1073\/PNAS.2107108118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6667_CR62","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1074\/JBC.M113.541110","volume":"289","author":"R Ruiz","year":"2014","unstructured":"Ruiz R, Jideonwo V, Ahn M et al (2014) Sterol Regulatory Element-binding Protein-1 (SREBP-1) Is Required to Regulate Glycogen Synthesis and Gluconeogenic Gene Expression in Mouse Liver. J Biol Chem 289:5510\u20135517. https:\/\/doi.org\/10.1074\/JBC.M113.541110","journal-title":"J Biol Chem"},{"key":"6667_CR63","doi-asserted-by":"publisher","unstructured":"Griffiths B, Lewis CA, Bensaad K et al (2013) Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab 1:1\u201321. https:\/\/doi.org\/10.1186\/2049-3002-1-3","DOI":"10.1186\/2049-3002-1-3"},{"key":"6667_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2023.1251705","volume":"14","author":"I Melano","year":"2023","unstructured":"Melano I, Lo YC, Su WC (2023) Characterization of host substrates of SARS-CoV-2 main protease. Front Microbiol 14:1\u20137. https:\/\/doi.org\/10.3389\/fmicb.2023.1251705","journal-title":"Front Microbiol"},{"key":"6667_CR65","doi-asserted-by":"publisher","first-page":"108312","DOI":"10.1016\/J.CELREP.2020.108312","volume":"33","author":"XLH Yong","year":"2020","unstructured":"Yong XLH, Cousin MA, Anggono V (2020) PICK1 Controls Activity-Dependent Synaptic Vesicle Cargo Retrieval. Cell Rep 33:108312. https:\/\/doi.org\/10.1016\/J.CELREP.2020.108312","journal-title":"Cell Rep"},{"key":"6667_CR66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/brainsci13010131","volume":"13","author":"MS Alqahtani","year":"2023","unstructured":"Alqahtani MS, Abbas M, Alshahrani MY et al (2023) Effects of COVID-19 on Synaptic and Neuronal Degeneration. Brain Sci 13:131. https:\/\/doi.org\/10.3390\/brainsci13010131","journal-title":"Brain Sci"},{"key":"6667_CR67","doi-asserted-by":"publisher","first-page":"17516","DOI":"10.1073\/PNAS.1312374110","volume":"110","author":"WC Su","year":"2013","unstructured":"Su WC, Chen YC, Tseng CH et al (2013) Pooled RNAi screen identifies ubiquitin ligase Itch as crucial for influenza A virus release from the endosome during virus entry. Proc Natl Acad Sci U S A 110:17516\u201317521. https:\/\/doi.org\/10.1073\/PNAS.1312374110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6667_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01043-6","volume":"71 7","author":"X Li","year":"2022","unstructured":"Li X, Zhang Z, Wang Z et al (2022) Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. Signal Transduct Target Ther 2022 71 7:1\u201321. https:\/\/doi.org\/10.1038\/s41392-022-01043-6","journal-title":"Signal Transduct Target Ther 2022"},{"key":"6667_CR69","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nature10744","volume":"4827385 482","author":"TLM Thurston","year":"2012","unstructured":"Thurston TLM, Wandel MP, Von Muhlinen N et al (2012) Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nat 2011 4827385 482:414\u2013418. https:\/\/doi.org\/10.1038\/nature10744","journal-title":"Nat 2011"},{"key":"6667_CR70","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1021\/ACSCENTSCI.3C00054","volume":"9","author":"SA Chen","year":"2023","unstructured":"Chen SA, Arutyunova E, Lu J et al (2023) SARS-CoV-2 Mpro Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. ACS Cent Sci 9:696\u2013708. https:\/\/doi.org\/10.1021\/ACSCENTSCI.3C00054","journal-title":"ACS Cent Sci"},{"key":"6667_CR71","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1042\/BST20200677","volume":"50","author":"Y Zick","year":"2022","unstructured":"Zick Y (2022) Galectin-8, cytokines, and the storm. Biochem Soc Trans 50:135\u2013149. https:\/\/doi.org\/10.1042\/BST20200677","journal-title":"Biochem Soc Trans"},{"key":"6667_CR72","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1080\/15548627.2022.2025570","volume":"18","author":"SY Khan","year":"2022","unstructured":"Khan SY, Ali M, Kabir F et al (2022) The role of FYCO1-dependent autophagy in lens fiber cell differentiation. Autophagy 18:2198\u20132215. https:\/\/doi.org\/10.1080\/15548627.2022.2025570","journal-title":"Autophagy"},{"key":"6667_CR73","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1080\/15548627.2023.2229656","volume":"19","author":"V Coppola","year":"2023","unstructured":"Coppola V, Marino I, Warnken U et al (2023) The autophagic protein FYCO1 controls TNFRSF10\/TRAIL receptor induced apoptosis and is inactivated by CASP8 (caspase 8). Autophagy 19:2733. https:\/\/doi.org\/10.1080\/15548627.2023.2229656","journal-title":"Autophagy"},{"key":"6667_CR74","doi-asserted-by":"publisher","first-page":"115080","DOI":"10.1016\/J.CELREP.2024.115080","volume":"43","author":"PM Grin","year":"2024","unstructured":"Grin PM, Baid K, de Jesus HCR et al (2024) SARS-CoV-2 3CLpro (main protease) regulates caspase activation of gasdermin-D\/E pores leading to secretion and extracellular activity of 3CLpro. Cell Rep 43:115080. https:\/\/doi.org\/10.1016\/J.CELREP.2024.115080","journal-title":"Cell Rep"},{"key":"6667_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/J.VIROL.2016.12.005","volume":"502","author":"X Zhu","year":"2017","unstructured":"Zhu X, Fang L, Wang D et al (2017) Porcine deltacoronavirus nsp5 inhibits interferon-\u03b2 production through the cleavage of NEMO. Virology 502:33\u201338. https:\/\/doi.org\/10.1016\/J.VIROL.2016.12.005","journal-title":"Virology"},{"key":"6667_CR76","doi-asserted-by":"publisher","unstructured":"Hameedi MA, Prates T, Garvin E et al (2022) MR, Structural and functional characterization of NEMO cleavage by SARS-CoV-2 3CLpro. Nat Commun 13:5285. https:\/\/doi.org\/10.1038\/s41467-022-32922-9","DOI":"10.1038\/s41467-022-32922-9"},{"key":"6667_CR77","doi-asserted-by":"publisher","first-page":"23626","DOI":"10.1074\/jbc.M112.347195","volume":"287","author":"T Kensche","year":"2012","unstructured":"Kensche T, Tokunaga F, Ikeda F et al (2012) Analysis of nuclear factor-\u03baB (NF-\u03baB) essential modulator (NEMO) binding to linear and lysine-linked ubiquitin chains and its role in the activation of NF-\u03baB. J Biol Chem 287:23626\u201323634. https:\/\/doi.org\/10.1074\/jbc.M112.347195","journal-title":"J Biol Chem"},{"key":"6667_CR78","doi-asserted-by":"publisher","unstructured":"Zhou Q, Zhang L, Dong Y et al (2023) The role of SARS-CoV-2-mediated NF-\u03baB activation in COVID-19 patients. Hypertens Res 47:375\u2013384. https:\/\/doi.org\/10.1038\/s41440-023-01460-2","DOI":"10.1038\/s41440-023-01460-2"},{"key":"6667_CR79","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/JMV.25915","volume":"92","author":"A Paniz-Mondolfi","year":"2020","unstructured":"Paniz-Mondolfi A, Bryce C, Grimes Z et al (2020) Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS\u2010CoV\u20102). J Med Virol 92:699. https:\/\/doi.org\/10.1002\/JMV.25915","journal-title":"J Med Virol"},{"key":"6667_CR80","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1056\/NEJMC2008597","volume":"382","author":"J Helms","year":"2020","unstructured":"Helms J, Kremer S, Merdji H et al (2020) Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med 382:2268\u20132270. https:\/\/doi.org\/10.1056\/NEJMC2008597","journal-title":"N Engl J Med"},{"key":"6667_CR81","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41593-021-00926-1","volume":"2411 24","author":"J Wenzel","year":"2021","unstructured":"Wenzel J, Lampe J, M\u00fcller-Fielitz H et al (2021) The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci 2021 2411 24:1522\u20131533. https:\/\/doi.org\/10.1038\/s41593-021-00926-1","journal-title":"Nat Neurosci 2021"},{"key":"6667_CR82","doi-asserted-by":"publisher","unstructured":"Yang J, Li Y, Wang S et al (2023) The SARS-CoV-2 main protease induces neurotoxic TDP-43 cleavage and aggregates. Signal Transduct Target Ther 8:1\u20134. https:\/\/doi.org\/10.1038\/s41392-023-01386-8","DOI":"10.1038\/s41392-023-01386-8"},{"key":"6667_CR83","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41583-021-00431-1","volume":"224 22","author":"P Tziortzouda","year":"2021","unstructured":"Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 2021 224 22:197\u2013208. https:\/\/doi.org\/10.1038\/s41583-021-00431-1","journal-title":"Nat Rev Neurosci 2021"},{"key":"6667_CR84","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/J.CHOM.2022.08.003","volume":"30","author":"S Iketani","year":"2022","unstructured":"Iketani S, Hong SJ, Sheng J et al (2022) Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Cell Host Microbe 30:1354\u20131362e6. https:\/\/doi.org\/10.1016\/J.CHOM.2022.08.003","journal-title":"Cell Host Microbe"},{"key":"6667_CR85","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1021\/ACS.JCIM.1C00449","volume":"61","author":"E Cho","year":"2021","unstructured":"Cho E, Rosa M, Anjum R et al (2021) Dynamic Profiling of \u03b2-Coronavirus 3CL MproProtease Ligand-Binding Sites. J Chem Inf Model 61:3058\u20133073. https:\/\/doi.org\/10.1021\/ACS.JCIM.1C00449","journal-title":"J Chem Inf Model"},{"key":"6667_CR86","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.chom.2022.08.003","volume":"30","author":"S Iketani","year":"2022","unstructured":"Iketani S, Hong SJ, Sheng J et al (2022) Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Cell Host Microbe 30:1362. https:\/\/doi.org\/10.1016\/j.chom.2022.08.003","journal-title":"Cell Host Microbe"},{"key":"6667_CR87","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/S11224-022-02089-6","volume":"34","author":"M Parmar","year":"2023","unstructured":"Parmar M, Thumar R, Patel B et al (2023) Structural differences in 3\u00a0C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations. Struct Chem 34:1309\u20131326. https:\/\/doi.org\/10.1007\/S11224-022-02089-6","journal-title":"Struct Chem"},{"key":"6667_CR88","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-021-03493-4","volume":"5947862 594","author":"A Stukalov","year":"2021","unstructured":"Stukalov A, Girault V, Grass V et al (2021) Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nat 2021 5947862 594:246\u2013252. https:\/\/doi.org\/10.1038\/s41586-021-03493-4","journal-title":"Nat 2021"},{"key":"6667_CR89","doi-asserted-by":"publisher","unstructured":"Scott BM, Lacasse V, Blom DG et al (2022) Predicted coronavirus Nsp5 protease cleavage sites in the human proteome. BMC Genomic Data 23:25. https:\/\/doi.org\/10.1186\/s12863-022-01044-y","DOI":"10.1186\/s12863-022-01044-y"},{"key":"6667_CR90","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1038\/s41467-024-51924-3","volume":"151 15","author":"M Nooruzzaman","year":"2024","unstructured":"Nooruzzaman M, Johnson KEE, Rani R et al (2024) Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. Nat Commun 2024 151 15:7999\u2013. https:\/\/doi.org\/10.1038\/s41467-024-51924-3","journal-title":"Nat Commun 2024"},{"key":"6667_CR91","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani S, Mohri H, Culbertson B et al (2023) Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613:558\u2013564. https:\/\/doi.org\/10.1038\/s41586-022-05514-2","journal-title":"Nature"},{"key":"6667_CR92","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"6227982 622","author":"Y Duan","year":"2023","unstructured":"Duan Y, Zhou H, Liu X et al (2023) Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nat 2023 6227982 622:376\u2013382. https:\/\/doi.org\/10.1038\/s41586-023-06609-0","journal-title":"Nat 2023"},{"key":"6667_CR93","doi-asserted-by":"publisher","unstructured":"Westberg M, Su Y, Zou X et al (2024) An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med 16. https:\/\/doi.org\/10.1126\/scitranslmed.adi0979","DOI":"10.1126\/scitranslmed.adi0979"},{"key":"6667_CR94","doi-asserted-by":"publisher","unstructured":"Iketani S, Forouhar F, Liu H et al (2021) Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun 2021 121. https:\/\/doi.org\/10.1038\/s41467-021-22362-2. 12:2016-","DOI":"10.1038\/s41467-021-22362-2"},{"key":"6667_CR95","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41467-022-29413-2","volume":"131 13","author":"H Liu","year":"2022","unstructured":"Liu H, Iketani S, Zask A et al (2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun 2022 131 13:1891. https:\/\/doi.org\/10.1038\/s41467-022-29413-2","journal-title":"Nat Commun 2022"},{"key":"6667_CR96","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41467-024-55421-5","volume":"161 16","author":"H Liu","year":"2025","unstructured":"Liu H, Zask A, Forouhar F et al (2025) Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. Nat Commun 2024 161 16:152. https:\/\/doi.org\/10.1038\/s41467-024-55421-5","journal-title":"Nat Commun 2024"},{"key":"6667_CR97","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1038\/s41467-024-50931-8","volume":"151 15","author":"MHJ Rhodin","year":"2024","unstructured":"Rhodin MHJ, Reyes AC, Balakrishnan A et al (2024) The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo. Nat Commun 2024 151 15:6503\u2013. https:\/\/doi.org\/10.1038\/s41467-024-50931-8","journal-title":"Nat Commun 2024"},{"key":"6667_CR98","unstructured":"Wang GSR et al (2026) US12540141B2 - Spiropyrrolidine derived antiviral agents - Google Patents"},{"key":"6667_CR99","doi-asserted-by":"publisher","first-page":"116629","DOI":"10.1016\/j.ejmech.2024.116629","volume":"275","author":"S Cheng","year":"2024","unstructured":"Cheng S, Feng Y, Li W et al (2024) Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses. Eur J Med Chem 275:116629. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116629","journal-title":"Eur J Med Chem"},{"key":"6667_CR100","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","volume":"67","author":"YR Alugubelli","year":"2024","unstructured":"Alugubelli YR, Xiao J, Khatua K et al (2024) Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. J Med Chem 67:6495\u20136507. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02416","journal-title":"J Med Chem"},{"key":"6667_CR101","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijms26083903","volume":"26","author":"C Wei","year":"2025","unstructured":"Wei C, Li Y, Guo L et al (2025) Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2. Int J Mol Sci 2025 26:26. https:\/\/doi.org\/10.3390\/ijms26083903","journal-title":"Int J Mol Sci 2025"},{"key":"6667_CR102","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.febslet.2004.08.015","volume":"574","author":"JTA Hsu","year":"2004","unstructured":"Hsu JTA, Kuo CJ, Hsieh HP et al (2004) Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS\u2010CoV. Febs Lett 574:116. https:\/\/doi.org\/10.1016\/j.febslet.2004.08.015","journal-title":"Febs Lett"},{"key":"6667_CR103","doi-asserted-by":"publisher","first-page":"10716","DOI":"10.1002\/anie.202016768","volume":"60","author":"J Karges","year":"2021","unstructured":"Karges J, Kalaj M, Gembicky M, Cohen SM (2021) ReI Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease. Angew Chemie - Int Ed 60:10716\u201310723. https:\/\/doi.org\/10.1002\/anie.202016768","journal-title":"Angew Chemie - Int Ed"},{"key":"6667_CR104","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biom12111675","volume":"12","author":"L Massai","year":"2022","unstructured":"Massai L, Grifagni D, Santis A, De et al (2022) Gold-Based Metal Drugs as Inhibitors of Coronavirus Proteins: The Inhibition of SARS-CoV-2 Main Protease by Auranofin and Its Analogs. Biomol 2022 12:12. https:\/\/doi.org\/10.3390\/biom12111675","journal-title":"Biomol 2022"},{"key":"6667_CR105","doi-asserted-by":"publisher","first-page":"113214","DOI":"10.1016\/j.jinorgbio.2026.113214","volume":"277","author":"X Jiang","year":"2026","unstructured":"Jiang X, Zhang H, Ping S et al (2026) Copper-polypyridine complexes as potent SARS-CoV-2 3CLpro inhibitors: Synthesis, evaluation, and molecular basis based on computational study. J Inorg Biochem 277:113214. https:\/\/doi.org\/10.1016\/j.jinorgbio.2026.113214","journal-title":"J Inorg Biochem"},{"key":"6667_CR106","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.joim.2022.08.001","volume":"20","author":"F Yang","year":"2022","unstructured":"Yang F, Jiang X, lan, Tariq A et al (2022) Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19. J Integr Med 20:488\u2013496. https:\/\/doi.org\/10.1016\/j.joim.2022.08.001","journal-title":"J Integr Med"},{"key":"6667_CR107","doi-asserted-by":"publisher","unstructured":"Heilmann E, Costacurta F, Moghadasi SA et al (2023) SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci Transl Med 15. https:\/\/doi.org\/10.1126\/scitranslmed.abq7360","DOI":"10.1126\/scitranslmed.abq7360"},{"key":"6667_CR108","doi-asserted-by":"publisher","first-page":"379456","DOI":"10.3389\/FIMMU.2018.01379","volume":"9","author":"HY Yong","year":"2018","unstructured":"Yong HY, Luo D (2018) RIG-I-like receptors as novel targets for pan-antivirals and vaccine adjuvants against emerging and re-emerging viral infections. Front Immunol 9:379456. https:\/\/doi.org\/10.3389\/FIMMU.2018.01379","journal-title":"Front Immunol"},{"key":"6667_CR109","doi-asserted-by":"publisher","first-page":"e1003298","DOI":"10.1371\/JOURNAL.PPAT.1003298","volume":"9","author":"ML Goulet","year":"2013","unstructured":"Goulet ML, Olagnier D, Xu Z et al (2013) Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity. PLOS Pathog 9:e1003298. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1003298","journal-title":"PLOS Pathog"},{"key":"6667_CR110","doi-asserted-by":"publisher","first-page":"496238","DOI":"10.3389\/FMICB.2019.03033","volume":"10","author":"Z Wang","year":"2020","unstructured":"Wang Z, Lu W, Zhang Y et al (2020) The Hippo Pathway and Viral Infections. Front Microbiol 10:496238. https:\/\/doi.org\/10.3389\/FMICB.2019.03033","journal-title":"Front Microbiol"},{"key":"6667_CR111","doi-asserted-by":"publisher","first-page":"e70338","DOI":"10.1002\/MCO2.70338","volume":"6","author":"R Bala","year":"2025","unstructured":"Bala R, Madaan R, Bedi O et al (2025) Targeting the Hippo\/YAP Pathway: A Promising Approach for Cancer Therapy and Beyond. MedComm 6:e70338. https:\/\/doi.org\/10.1002\/MCO2.70338","journal-title":"MedComm"},{"key":"6667_CR112","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.7150\/THNO.40889","volume":"10","author":"AV Pobbati","year":"2020","unstructured":"Pobbati AV, Hong W (2020) A combat with the YAP\/TAZ-TEAD oncoproteins for cancer therapy. Theranostics 10:3622. https:\/\/doi.org\/10.7150\/THNO.40889","journal-title":"Theranostics"},{"key":"6667_CR113","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/MICROORGANISMS9030540","volume":"9","author":"G Taroncher-oldenburg","year":"2021","unstructured":"Taroncher-oldenburg G, M\u00fcller C, Obermann W et al (2021) Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates\u2014A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics. Microorganisms 9:540. https:\/\/doi.org\/10.3390\/MICROORGANISMS9030540","journal-title":"Microorganisms"},{"key":"6667_CR114","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/J.CHEMBIOL.2019.08.008","volume":"26","author":"J Chu","year":"2019","unstructured":"Chu J, Zhang W, Cencic R et al (2019) Amidino-Rocaglates \u2013 A potent class of eIF4A inhibitors. Cell Chem Biol 26:1586. https:\/\/doi.org\/10.1016\/J.CHEMBIOL.2019.08.008","journal-title":"Cell Chem Biol"},{"key":"6667_CR115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.15212\/AMM-2025-0001","volume":"4","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xiao H, Lai L, Zheng Z (2025) Therapeutic strategies targeting SREBP transcription factors: an update to 2024. Acta Mater Med 4:437\u2013465. https:\/\/doi.org\/10.15212\/AMM-2025-0001","journal-title":"Acta Mater Med"},{"key":"6667_CR116","doi-asserted-by":"publisher","first-page":"177890","DOI":"10.1016\/J.EJPHAR.2025.177890","volume":"1003","author":"M Arora","year":"2025","unstructured":"Arora M, Canov\u00e1 N, \u0160opin T et al (2025) Effectiveness and safety of the SREBP1\/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progression. Eur J Pharmacol 1003:177890. https:\/\/doi.org\/10.1016\/J.EJPHAR.2025.177890","journal-title":"Eur J Pharmacol"},{"key":"6667_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41419-021-03762-0","volume":"12","author":"X Ma","year":"2021","unstructured":"Ma X, Zhao T, Yan H et al (2021) Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-\u03baB pathway in endometrial carcinoma. Cell Death Dis 12:1\u201321. https:\/\/doi.org\/10.1038\/S41419-021-03762-0","journal-title":"Cell Death Dis"},{"key":"6667_CR118","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/S44319-024-00346-9","volume":"26","author":"T Nishimura","year":"2025","unstructured":"Nishimura T, Kouwaki T, Takashima K et al (2025) Cholesterol restriction primes antiviral innate immunity via SREBP1-driven noncanonical type I IFNs. EMBO Rep 26:560\u2013592. https:\/\/doi.org\/10.1038\/S44319-024-00346-9","journal-title":"EMBO Rep"},{"key":"6667_CR119","doi-asserted-by":"publisher","unstructured":"Liu S, Luo A, Que T et al (2025) Negative regulation of SREBP-1\/FAS signaling molecules activates the RIG-1\/TBK1-mediated IFN-I pathway to inhibit BVDV replication. Antiviral Res 233. https:\/\/doi.org\/10.1016\/j.antiviral.2024.106054","DOI":"10.1016\/j.antiviral.2024.106054"},{"key":"6667_CR120","doi-asserted-by":"publisher","unstructured":"Nhau PT, Gamede M, Khathi A, Sibiya N (2025) SARS-CoV-2 Main Protease Dysregulates Hepatic Insulin Signaling and Glucose Uptake: Implications for Post-COVID-19 Diabetogenesis. Pathophysiol 32:39. https:\/\/doi.org\/10.3390\/PATHOPHYSIOLOGY32030039","DOI":"10.3390\/PATHOPHYSIOLOGY32030039"},{"key":"6667_CR121","doi-asserted-by":"publisher","first-page":"e80749","DOI":"10.1172\/JCI.INSIGHT.80749","volume":"1","author":"A Kuznetsova","year":"2016","unstructured":"Kuznetsova A, Yu Y, Hollister-Lock J et al (2016) Trimeprazine increases IRS2 in human islets and promotes pancreatic \u03b2 cell growth and function in mice. JCI Insight 1:e80749. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.80749","journal-title":"JCI Insight"},{"key":"6667_CR122","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1530\/JOE-15-0409","volume":"229","author":"H Xu","year":"2016","unstructured":"Xu H, Zhou Y, Liu Y et al (2016) Metformin improves hepatic IRS2\/PI3K\/Akt signaling in insulin-resistant rats of NASH and cirrhosis. J Endocrinol 229:133\u2013144. https:\/\/doi.org\/10.1530\/JOE-15-0409","journal-title":"J Endocrinol"},{"key":"6667_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S43556-022-00083-2","volume":"3","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu S, Xu Q et al (2022) Cleavage of the selective autophagy receptor SQSTM1\/p62 by the SARS-CoV-2 main protease NSP5 prevents the autophagic degradation of viral membrane proteins. Mol Biomed 3:1\u201313. https:\/\/doi.org\/10.1186\/S43556-022-00083-2","journal-title":"Mol Biomed"},{"key":"6667_CR124","doi-asserted-by":"publisher","unstructured":"Waisner H, Grieshaber B, Saud R et al (2023) SARS-CoV-2 Harnesses Host Translational Shutoff and Autophagy To Optimize Virus Yields: the Role of the Envelope (E) Protein. https:\/\/doi.org\/10.1128\/SPECTRUM.03707-22. Microbiol Spectr 11:","DOI":"10.1128\/SPECTRUM.03707-22"},{"key":"6667_CR125","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/15548627.2022.2116677","volume":"19","author":"Q Sun","year":"2023","unstructured":"Sun Q, Li X, Kuang E (2023) Subversion of autophagy machinery and organelle-specific autophagy by SARS-CoV-2 and coronaviruses. Autophagy 19:1055\u20131069. https:\/\/doi.org\/10.1080\/15548627.2022.2116677","journal-title":"Autophagy"},{"key":"6667_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41467-021-24007-W","volume":"12","author":"NC Gassen","year":"2021","unstructured":"Gassen NC, Papies J, Bajaj T et al (2021) SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat Commun 12:1\u201315. https:\/\/doi.org\/10.1038\/S41467-021-24007-W","journal-title":"Nat Commun"},{"key":"6667_CR127","doi-asserted-by":"publisher","first-page":"e01020","DOI":"10.1128\/MBIO.01020-23","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou H, Hu Z, Castro-Gonzalez S (2023) Bidirectional interplay between SARS-CoV-2 and autophagy. MBio 14:e01020\u2013e01023. https:\/\/doi.org\/10.1128\/MBIO.01020-23","journal-title":"MBio"},{"key":"6667_CR128","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/J.JTCME.2021.10.003","volume":"12","author":"C Vidoni","year":"2022","unstructured":"Vidoni C, Fuzimoto A, Ferraresi A, Isidoro C (2022) Targeting autophagy with natural products to prevent SARS-CoV-2 infection. J Tradit Complement Med 12:55\u201368. https:\/\/doi.org\/10.1016\/J.JTCME.2021.10.003","journal-title":"J Tradit Complement Med"},{"key":"6667_CR129","doi-asserted-by":"publisher","first-page":"2195020","DOI":"10.1080\/22221751.2023.2195020","volume":"12","author":"APM Cloherty","year":"2023","unstructured":"Cloherty APM, Rader AG, Patel KS et al (2023) Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade. Emerg Microbes Infect 12:2195020. https:\/\/doi.org\/10.1080\/22221751.2023.2195020","journal-title":"Emerg Microbes Infect"},{"key":"6667_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41392-021-00749-3","volume":"6","author":"Y Jing","year":"2021","unstructured":"Jing Y, Luo L, Chen Y et al (2021) SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism. Signal Transduct Target Ther 6:1\u201313. https:\/\/doi.org\/10.1038\/S41392-021-00749-3","journal-title":"Signal Transduct Target Ther"},{"key":"6667_CR131","doi-asserted-by":"publisher","first-page":"1367974","DOI":"10.3389\/FNEUR.2024.1367974","volume":"15","author":"J Zhao","year":"2024","unstructured":"Zhao J, Xia F, Jiao X, Lyu X (2024) Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment. Front Neurol 15:1367974. https:\/\/doi.org\/10.3389\/FNEUR.2024.1367974","journal-title":"Front Neurol"},{"key":"6667_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00415-025-13110-3","volume":"272","author":"D Bereczki","year":"2025","unstructured":"Bereczki D, D\u00e9nes \u00c1, Boneschi FM et al (2025) Need for awareness and surveillance of long-term post-COVID neurodegenerative disorders. A position paper from the neuroCOVID-19 task force of the European Academy of Neurology. J Neurol 272:1\u201312. https:\/\/doi.org\/10.1007\/S00415-025-13110-3","journal-title":"J Neurol"},{"key":"6667_CR133","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/VACCINES12030222","volume":"12","author":"D Bedran","year":"2024","unstructured":"Bedran D, Bedran G, Kote S (2024) A Comprehensive Review of Neurodegenerative Manifestations of SARS-CoV-2. Vaccines 12:222. https:\/\/doi.org\/10.3390\/VACCINES12030222","journal-title":"Vaccines"},{"key":"6667_CR134","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/d41586-025-02420-1","volume":"644","author":"M Kozlov","year":"2025","unstructured":"Kozlov M (2025) Sleeping\u2019 cancer cells in the lungs can be roused by COVID and flu. Nature 644:314\u2013315. https:\/\/doi.org\/10.1038\/d41586-025-02420-1","journal-title":"Nature"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-026-06667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-026-06667-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-026-06667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:02:40Z","timestamp":1785135760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-026-06667-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":134,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["6667"],"URL":"https:\/\/doi.org\/10.1007\/s00705-026-06667-5","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The 3rd last line on the first page of the article, the abbreviation to be updated as TAB 1 instead of Table 1.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"202"}}